John P. Iwanicki comments on a drug commercialization agreement between ImClone and Bristol-Myers in a Dow Jones Newswire article. The article appeared in SmartMoney, The Wall Street Journal and CNNMoney.

The article discusses ImClone and Bristol-Myers dispute over cancer treatment drugs Erbitux and IMC-11F8. Iwanicki states that  ImClone could begin developing or commercializing IMC-11F8 in the U.S. after September 2008 when ban on competing products expires.

Please click here to view the article.

Posted: August 10, 2008